Brooklyn Investment Group Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Brooklyn Investment Group purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 413 shares of the biopharmaceutical company’s stock, valued at approximately $114,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. TD Asset Management Inc raised its position in Alnylam Pharmaceuticals by 6.0% in the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock worth $119,055,000 after acquiring an additional 27,592 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after acquiring an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares in the last quarter. Swiss National Bank raised its position in Alnylam Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its position in Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,370 shares of company stock worth $2,100,703. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on ALNY shares. TD Cowen boosted their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Raymond James boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ ALNY opened at $253.74 on Thursday. The stock has a market cap of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39. The business has a 50 day simple moving average of $272.32 and a 200 day simple moving average of $240.10. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the prior year, the business posted $1.15 EPS. The business’s revenue was down 33.3% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.